EP2300004A4 - Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof - Google Patents

Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof

Info

Publication number
EP2300004A4
EP2300004A4 EP09747702A EP09747702A EP2300004A4 EP 2300004 A4 EP2300004 A4 EP 2300004A4 EP 09747702 A EP09747702 A EP 09747702A EP 09747702 A EP09747702 A EP 09747702A EP 2300004 A4 EP2300004 A4 EP 2300004A4
Authority
EP
European Patent Office
Prior art keywords
targets
compositions
transcription factor
heat shock
methods relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09747702A
Other languages
German (de)
French (fr)
Other versions
EP2300004A2 (en
Inventor
Dennis J Thiele
Daniel W Neef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US5351308P priority Critical
Application filed by Duke University filed Critical Duke University
Priority to PCT/US2009/044186 priority patent/WO2009140621A2/en
Publication of EP2300004A2 publication Critical patent/EP2300004A2/en
Publication of EP2300004A4 publication Critical patent/EP2300004A4/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring-systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
EP09747702A 2008-05-15 2009-05-15 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof Withdrawn EP2300004A4 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US5351308P true 2008-05-15 2008-05-15
PCT/US2009/044186 WO2009140621A2 (en) 2008-05-15 2009-05-15 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof

Publications (2)

Publication Number Publication Date
EP2300004A2 EP2300004A2 (en) 2011-03-30
EP2300004A4 true EP2300004A4 (en) 2012-05-30

Family

ID=41319361

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09747702A Withdrawn EP2300004A4 (en) 2008-05-15 2009-05-15 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof

Country Status (4)

Country Link
EP (1) EP2300004A4 (en)
CN (1) CN102088973A (en)
CA (1) CA2724413C (en)
WO (1) WO2009140621A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
RU2576036C2 (en) 2010-03-17 2016-02-27 Тайвекс Терапьютикс Корпорейшн Modulators of hec1 activity and methods therefor
RU2639876C2 (en) 2010-03-30 2017-12-25 Версеон Корпорейшн Multi-substituted aromatic compounds as thrombin inhibitors
SG11201402143YA (en) 2011-11-21 2014-06-27 Taivex Therapeutics Corp Biomarkers for cancers responsive to modulators of hec1 activity
KR20150132148A (en) 2013-03-15 2015-11-25 베르선 코포레이션 Multisubstituted aromatic compounds as serine protease inhibitors
CN105209440B (en) 2013-03-15 2019-07-23 维颂公司 Halo-pyrazole as thrombin inhibitor
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
SG11201701940UA (en) 2014-09-17 2017-04-27 Verseon Corp Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
WO2017019772A1 (en) * 2015-07-27 2017-02-02 Sanford Burnham Prebys Medical Discovery Institute Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof
CN105524056A (en) * 2016-01-05 2016-04-27 中山大学肿瘤防治中心 Aminothiazole compound, and preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110350A2 (en) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2005026137A2 (en) * 2003-09-06 2005-03-24 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2005041879A2 (en) * 2003-10-28 2005-05-12 Pharmacia Corporation COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA
WO2005044194A2 (en) * 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
WO2006013054A1 (en) * 2004-08-05 2006-02-09 F. Hoffmann-La Roche Ag Substituted n-acyl-2-aminothiazoles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
US7919603B2 (en) * 2005-12-19 2011-04-05 New York University Heat shock RNA

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110350A2 (en) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2005026137A2 (en) * 2003-09-06 2005-03-24 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2005041879A2 (en) * 2003-10-28 2005-05-12 Pharmacia Corporation COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA
WO2005044194A2 (en) * 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
WO2006013054A1 (en) * 2004-08-05 2006-02-09 F. Hoffmann-La Roche Ag Substituted n-acyl-2-aminothiazoles

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BATULAN Z ET AL: "Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 24, no. 2, 1 November 2006 (2006-11-01), pages 213 - 225, XP024901478, ISSN: 0969-9961, [retrieved on 20061101], DOI: 10.1016/J.NBD.2006.06.017 *
DANIEL W. NEEF ET AL: "Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases", NATURE REVIEWS DRUG DISCOVERY, vol. 10, no. 12, 1 January 2011 (2011-01-01), pages 930 - 944, XP055024215, ISSN: 1474-1776, DOI: 10.1038/nrd3453 *
GALAM ET AL: "High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 15, no. 5, 31 January 2007 (2007-01-31), pages 1939 - 1946, XP005867161, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2007.01.004 *
LEONE S ET AL: "SAR and QSAR study on 2-aminothiazole derivatives, modulators of transcriptional repression in Huntington's disease", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 16, no. 10, 30 March 2008 (2008-03-30), pages 5695 - 5703, XP022673151, ISSN: 0968-0896, [retrieved on 20080330], DOI: 10.1016/J.BMC.2008.03.067 *
NEEF DANIEL W ET AL: "Modulation of Heat Shock Transcription Factor 1 as a Therapeutic Target for Small Molecule Intervention in Neurodegenerative Disease", PLOS BIOLOGY, vol. 8, no. 1, January 2010 (2010-01-01), XP002673717 *
POWERS ET AL: "Inhibitors of the heat shock response: Biology and pharmacology", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 581, no. 19, 31 July 2007 (2007-07-31), pages 3758 - 3769, XP022191504, ISSN: 0014-5793, DOI: 10.1016/J.FEBSLET.2007.05.040 *
SALEHI A H ET AL: "AEG3482 Is an Antiapoptotic Compound that Inhibits Jun Kinase Activity and Cell Death through Induced Expression of Heat Shock Protein 70", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 13, no. 2, 1 February 2006 (2006-02-01), pages 213 - 223, XP025131819, ISSN: 1074-5521, [retrieved on 20060201], DOI: 10.1016/J.CHEMBIOL.2005.11.012 *
TROTT AMY ET AL: "Activation of heat shock and antioxidant responses by the natural product celastrol: Transcriptional signatures of a thiol-targeted molecule", MOLECULAR BIOLOGY OF THE CELL, vol. 19, no. 3, March 2008 (2008-03-01), pages 1104 - 1112, XP002673716, ISSN: 1059-1524 *
WESTERHEIDE SANDY D ET AL: "Heat shock response modulators as therapeutic tools for diseases of protein conformation", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC, US, vol. 280, no. 39, 1 September 2005 (2005-09-01), pages 33097 - 33100, XP002637231, ISSN: 0021-9258, DOI: 10.1074/JBC.R500010200 *

Also Published As

Publication number Publication date
EP2300004A2 (en) 2011-03-30
WO2009140621A8 (en) 2011-05-12
CA2724413C (en) 2016-10-18
CN102088973A (en) 2011-06-08
WO2009140621A2 (en) 2009-11-19
CA2724413A1 (en) 2009-11-19
WO2009140621A3 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
DK2257624T3 (en) Methods and compositions
AP3106A (en) Antiparisitic dihydroazole compounds and compositions comprising same
HK1162378A1 (en) Tetrafluoropropene compositions and uses thereof
HK1216652A1 (en) Compositions and methods for inhibiting expression of transthyretin
GB0712988D0 (en) Improvements in or relating to compositions
ZA201005268B (en) Composition
EP2148858A4 (en) Inhibitors of iap
BRPI0914652A2 (en) compounds and compositions as kinase inhibitors
GB0808239D0 (en) Compositions
HUE026605T2 (en) Heat transfer compositions and methods
HK1149005A1 (en) Azetidine and cyclobutane derivatives as jak inhibitors jak
ZA201200054B (en) Therapeutic compounds and compositions
HRP20161606T1 (en) Novel method and compositions
HK1172326A1 (en) Compounds and compositions and methods of use
SI2161038T1 (en) Compositions and their uses directed to Huntingtin
BRPI0908348A2 (en) Methods and kits of compositions for enhancing the immune response to a respiratory condition
IL218057D0 (en) Compositions comprising carboxamide compounds and uses thereof
EP2475632A4 (en) Monochlorotrifluoropropene compounds and compositions and methods using same
EP2307553A4 (en) Methods and compositions for the recombinant biosynthesis of n-alkanes
GB0815022D0 (en) Composition
EP2483362A4 (en) Fluoropropene compounds and compositions and methods using same
EP2448413A4 (en) Slow release magnesium composition and uses thereof
IL208457D0 (en) Compositions and methods for the preparation of nanoemulsions
ZA201008232B (en) Lipid-containing compositions and methods of use thereof
SI2320911T1 (en) Vasoconstriction compositions and methods of use

Legal Events

Date Code Title Description
AX Request for extension of the european patent to

Extension state: AL BA RS

17P Request for examination filed

Effective date: 20101214

AK Designated contracting states:

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

RIC1 Classification (correction)

Ipc: C07D 277/60 20060101ALI20120418BHEP

Ipc: A61K 31/4155 20060101ALI20120418BHEP

Ipc: A61K 31/415 20060101AFI20120418BHEP

Ipc: A61K 31/426 20060101ALI20120418BHEP

Ipc: A61K 45/06 20060101ALI20120418BHEP

Ipc: A61P 25/28 20060101ALI20120418BHEP

Ipc: C07D 277/38 20060101ALI20120418BHEP

Ipc: A61P 25/16 20060101ALI20120418BHEP

Ipc: A61P 35/00 20060101ALI20120418BHEP

A4 Despatch of supplementary search report

Effective date: 20120502

17Q First examination report

Effective date: 20131205

18D Deemed to be withdrawn

Effective date: 20180213